Navigation Links
Some cancer drugs may block cellular 'cross talk' but not kill cancer cells
Date:12/22/2010

AURORA, Colo. (Dec. 22, 2010)A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spreada discovery that could significantly alter the way cancer drugs are evaluated in the future.

Researchers at the University of Colorado Cancer Center demonstrated the discovery in bladder cancer, the fifth most common cancer in the United States. Bladder cancer will kill about 14,000 Americans this year, most of whom will die as a result of the disease's spread to other organs in a process called metastasis.

The scientists showed that endothelin-A receptor antagonist drugs are only effective at blocking the start of cancer spread to other organs, not treating large, established primary-or distant-site tumors. The study was published online Dec. 22, 2010, in the Journal of Clinical Investigation.

"We discovered that these drugs block the 'tumor host interactions' found at sites of metastasis, which is what reduces tumor growth at these sites," said lead author Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and professor of surgery and pharmacology at the University of Colorado School of Medicine. "However, unless the drugs are used early, they have minimal or no effect."

Endothelin-A receptor antagonist drugs block the action of a protein called endothelin 1 [ET-1], thought to be involved in stimulating cancer cell growth and spread. Theodorescu's lab discovered that ET-1 attracts immune cells called macrophages to cancer cells lodged in the lungs. The macrophages start making factors that stimulate the cancer cells in the lungs to growcalled metastatic colonizationwhich significantly decreases the patient's chance of survival.

In the past decade, two endothelin-A receptor antagonist drugsAbbott's atrasentan and AstraZeneca's zibotentanhave had difficulties in large phase 3 clinical trials. Both drugs were tested in a large number of patients with advanced cancer, and neither drug attained its desired effects. Most likely, Theodorescu said, the drugs were given after the window of opportunity for them to work had closed.

"Had we known this before the trials, we wouldn't have used them to try to reduce large, established tumors," he said. "We would have used them to try to suppress the appearance of metastasis. This new information has important implications for how we test drugs for effectiveness before human use and then on how we select patients in clinical trials with these agents, especially since many types of cancer secrete ET-1."


'/>"/>

Contact: Caitlin Jenney
caitlin.jenney@ucdenver.edu
303-315-6376
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Researchers discover genetic predisposition for breast, kidney cancers
2. Damon Runyon Cancer Research Foundation awards breakthrough scientists
3. Key information about breast cancer risk and development is found in junk DNA
4. Scientists discover powerful biomarker panel for the early detection of breast cancer
5. Blocking the critical structure that lets cancer cells move -- their feet
6. Missing molecules hold promise of therapy for pancreatic cancer
7. Scientists identify how virus triggers cervical and mouth cancer
8. A protein called cFLIP makes tumor cells in breast cancer resistant to treatments
9. Study: Osteoporosis drug reduces bone loss, tumor size in oral cancer
10. Ovarian cancer screening saves few lives
11. UCR scientists identify pomegranate juice components that could stop cancer from spreading
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... 09, 2017 , ... The Giving Tree Wellness Center announces ... needs of consumers who are incorporating medical marijuana into their wellness and health ... As operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma ... Cancer Institute. The event is free and open to the public, but registration ...
Breaking Biology Technology: